Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsSubmitted by Nathan Reiff. Originally Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take niche approaches, developing medicines to target specific cancers with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of sizable sales. Two smaller biotech companies are experiencing strong share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic promise, these drugs could help the firms move beyond penny-stock status and toward greater stability and eventual profitability. That said, both remain typical biotech investments in many ways—high-risk ventures that also offer the possibility of outsized rewards for investors willing to take a chance. Iovance's Promising Cancer Drug Is Growing, but Production Challenges Remain Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, surging nearly 37% in a week when the S&P 500 dropped about 1%. That added to Iovance's year-to-date (YTD) gains, which have seen shares more than double. Still, with a consensus price target of $8.88, Wall Street appears to expect more—the target implies roughly 71% upside from current levels. The main catalyst for Iovance's move is its lead product, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the United States in 2024 and has built momentum—both in sales and with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company believes Amtagvi could achieve more than $1 billion in peak U.S. sales. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track Designation for non-small cell lung cancer and is being evaluated for other tumor types. Some of Iovance's outperformance this year also follows its Q4 2025 earnings report, released in late February, which showed a smaller-than-expected loss per share and $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance remains a relatively small (~$2 billion) biotech and, technically, a penny stock. Despite this year's rally, analysts remain cautious—about half of the firm's roughly dozen ratings are Hold or Sell. Risks are elevated: beyond the usual concerns for smaller biotechs, Amtagvi's personalized, costly, and complex manufacturing process could constrain profitability even if demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell roughly 20% in March, but its YTD performance still dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic—the consensus price target of $13.60 suggests about 70% upside from current levels. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization, the latest in a string of approvals worldwide. Anktiva is driving revenue: it produced $113 million in sales last year, roughly a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer types; ImmunityBio is actively exploring additional indications. Despite the recent surge, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as R&D spending continues to rise. Analysts are somewhat more bullish on ImmunityBio than on Iovance—six of seven rate IBRX a Buy or equivalent—but the risks are material. Both companies demonstrate the upside potential of oncology-focused biotechs but also highlight the sector's volatility. Investors should weigh the clinical and commercial promise against manufacturing, regulatory, and financial risks and consider consulting a financial advisor before making investment decisions. | 
